$10.11
+0.00 (+0.00%)
DMII News11 articles
Pfizer Stock Rises 7% as Non-COVID Drugs Offset Pandemic Revenue Decline
Pfizer shares rose 7% last week, driven by strong performance from Eliquis and other key drugs that offset declining COVID product sales.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
TrumpRx Expansion to 800+ Drugs Heightens Tariff Risk for Generic Makers
Generic drug stocks fell after Trump announced tariffs up to 200% on imports by 2029, as TrumpRx expands to over 800 medications with 79 brand deals.
J&J's Q2 Growth Largely Relies on Two Key Drugs
Johnson & Johnson's Q2 sales growth was almost entirely driven by Tremfya and Darzalex, raising concerns about portfolio depth. MedTech missed estimates.
Pfizer's Recovery Play: Can New Drugs Offset Patent Cliff?
Pfizer stock gains on Q1 beat and steady outlook, but investors weigh patent cliff risks against new oncology and GLP-1 drug prospects.
Teva Surges 11% as Branded Drugs Drive Q1 Beat, Emalex Deal Adds Tourette Candidate
Teva beat Q1 estimates with adjusted EPS of $0.53 on $3.98B revenue, as branded drug sales surged 41%. Shares rose 11% on the news.
Biogen Acquires Apellis in $5.6B Deal, Adding Eye and Kidney Drugs
Biogen has entered a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion. The deal includes a $41 per share cash offer plus contingent value rights.
Vertex Shares Slide on Updated Safety Warnings for CF Drugs
Vertex Pharmaceuticals shares declined 4.6% to $433.07 following updated U.S. safety labels for its cystic fibrosis drugs citing serious neuropsychiatric events. The company maintains its 2026 revenue outlook remains heavily dependent on CF treatments.
Hims & Hers Shares Extend Decline Amid Novo Nordisk Patent Lawsuit Over Compounded Weight-Loss Drugs
Hims & Hers Health stock fell another 5.6% as Novo Nordisk filed a patent lawsuit seeking to block compounded versions of Wegovy, tightening regulatory pressure on the online health provider's GLP-1 offerings.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.